6 results on '"Chamoun, Mira"'
Search Results
2. Medial temporal tau predicts memory decline in cognitively unimpaired elderly.
- Author
-
Kwan, Angela T. H., Arfaie, Saman, Therriault, Joseph, Azizi, Zahra, Lussier, Firoza Z., Tissot, Cecile, Chamoun, Mira, Bezgin, Gleb, Servaes, Stijn, Stevenon, Jenna, Rahmouni, Nesrine, Pallen, Vanessa, Gauthier, Serge, and Rosa-Neto, Pedro
- Published
- 2023
- Full Text
- View/download PDF
3. Longitudinal 18F-MK-6240 tau tangles accumulation follows Braak stages.
- Author
-
Pascoal, Tharick A, Benedet, Andrea L, Tudorascu, Dana L, Therriault, Joseph, Mathotaarachchi, Sulantha, Savard, Melissa, Lussier, Firoza Z, Tissot, Cécile, Chamoun, Mira, Kang, Min Su, Stevenson, Jenna, Massarweh, Gassan, Guiot, Marie-Christine, Soucy, Jean-Paul, Gauthier, Serge, and Rosa-Neto, Pedro
- Subjects
NEUROFIBRILLARY tangles ,FRONTOTEMPORAL lobar degeneration ,CEREBRAL amyloid angiopathy ,ALZHEIMER'S patients ,ALZHEIMER'S disease ,SENSORIMOTOR cortex ,MILD cognitive impairment ,RESEARCH ,NEURONS ,NERVE tissue proteins ,RESEARCH methodology ,ISOQUINOLINE ,RADIOISOTOPES ,EVALUATION research ,FLUORINE isotopes ,COMPARATIVE studies ,RADIOPHARMACEUTICALS ,RESEARCH funding ,NEURORADIOLOGY ,NEURODEGENERATION ,EMISSION-computed tomography ,PEPTIDES - Abstract
Tracking longitudinal tau tangles accumulation across the Alzheimer's disease continuum is crucial to better understand the natural history of tau pathology and for clinical trials. Although the available first-generation tau PET tracers detect tau accumulation in symptomatic individuals, their nanomolar affinity offers limited sensitivity to detect early tau accumulation in asymptomatic subjects. Here, we hypothesized the novel subnanomolar affinity tau tangles tracer 18F-MK-6240 can detect longitudinal tau accumulation in asymptomatic and symptomatic subjects. We studied 125 living individuals (65 cognitively unimpaired elderly amyloid-β-negative, 22 cognitively unimpaired elderly amyloid-β-positive, 21 mild cognitive impairment amyloid-β-positive and 17 Alzheimer's disease dementia amyloid-β-positive individuals) with baseline amyloid-β 18F-AZD4694 PET and baseline and follow-up tau 18F-MK-6240 PET. The 18F-MK-6240 standardized uptake value ratio (SUVR) was calculated at 90-110 min after tracer injection and the cerebellar crus I was used as the reference region. In addition, we assessed the in vivo18F-MK-6240 SUVR and post-mortem phosphorylated tau pathology in two participants with Alzheimer's disease dementia who died after the PET scans. We found that the cognitively unimpaired amyloid-β-negative individuals had significant longitudinal tau accumulation confined to the PET Braak-like stage I (3.9%) and II (2.8%) areas. The cognitively unimpaired amyloid-β-positive individuals showed greater tau accumulation in Braak-like stage I (8.9%) compared with later Braak stages. The patients with mild cognitive impairment and those who were Alzheimer's dementia amyloid-β-positive exhibited tau accumulation in Braak regions III-VI but not I-II. Cognitively impaired amyloid-β-positive individuals that were Braak II-IV at baseline displayed a 4.6-7.5% annual increase in tau accumulation in the Braak III-IV regions, whereas those who were cognitively impaired amyloid-β-positive Braak V-VI at baseline showed an 8.3-10.7% annual increase in the Braak regions V-VI. Neuropathological assessments confirmed PET-based Braak stages V-VI in the two brain donors. Our results suggest that the 18F-MK-6240 SUVR is able to detect longitudinal tau accumulation in asymptomatic and symptomatic Alzheimer's disease. The highest magnitude of 18F-MK-6240 SUVR accumulation moved from the medial temporal to sensorimotor cortex across the disease clinical spectrum. Trials using the 18F-MK-6240 SUVR in cognitively unimpaired individuals would be required to use regions of interest corresponding to early Braak stages, whereas trials in cognitively impaired subjects would benefit from using regions of interest associated with late Braak stages. Anti-tau trials should take into consideration an individual's baseline PET Braak-like stage to minimize the variability introduced by the hierarchical accumulation of tau tangles in the human brain. Finally, our post-mortem findings supported use of the 18F-MK-6240 SUVR as a biomarker to stage tau pathology in patients with Alzheimer's disease. [ABSTRACT FROM AUTHOR]
- Published
- 2021
- Full Text
- View/download PDF
4. Association of plasma P-tau181 with memory decline in non-demented adults.
- Author
-
Therriault, Joseph, Benedet, Andrea L., Pascoal, Tharick A., Lussier, Firoza Z., Tissot, Cecile, Karikari, Thomas K., Ashton, Nicholas J., Chamoun, Mira, Bezgin, Gleb, Mathotaarachchi, Sulantha, Gauthier, Serge, Saha-Chaudhuri, Paramita, Zetterberg, Henrik, Blennow, Kaj, and Rosa-Neto, Pedro
- Published
- 2021
- Full Text
- View/download PDF
5. Stage-specific links between plasma neurofilament light and imaging biomarkers of Alzheimer's disease.
- Author
-
Benedet, Andréa L, Leuzy, Antoine, Pascoal, Tharick A, Ashton, Nicholas J, Mathotaarachchi, Sulantha, Savard, Melissa, Therriault, Joseph, Kang, Min Su, Chamoun, Mira, Schöll, Michael, Zimmer, Eduardo R, Gauthier, Serge, Labbe, Aurélie, Zetterberg, Henrik, Rosa-Neto, Pedro, Blennow, Kaj, Initiative, for the Alzheimer's Disease Neuroimaging, and Alzheimer’s Disease Neuroimaging Initiative
- Subjects
ALZHEIMER'S disease ,CYTOPLASMIC filaments ,SINGLE molecules ,CEREBRAL atrophy ,MILD cognitive impairment ,CLINICAL drug trials - Abstract
Neurofilament light (NfL) is a marker of neuroaxonal injury, a prominent feature of Alzheimer's disease. It remains uncertain, however, how it relates to amyloid and tau pathology or neurodegeneration across the Alzheimer's disease continuum. The aim of this study was to investigate how plasma NfL relates to amyloid and tau PET and MRI measures of brain atrophy in participants with and without cognitive impairment. We retrospectively examined the association between plasma NfL and MRI measures of grey/white matter volumes in the Alzheimer's Disease Neuroimaging Initiative [ADNI: n = 1149; 382 cognitively unimpaired control subjects and 767 cognitively impaired participants (mild cognitive impairment n = 420, Alzheimer's disease dementia n = 347)]. Longitudinal plasma NfL was measured using single molecule array (Simoa) technology. Cross-sectional associations between plasma NfL and PET amyloid and tau measures were independently assessed in two cohorts: ADNI [n = 198; 110 cognitively unimpaired, 88 cognitively impaired (MCI n = 67, Alzheimer's disease dementia n = 21), data accessed October 2018]; and Translational Biomarkers in Aging and Dementia [TRIAD, n = 116; 74 cognitively unimpaired, 42 cognitively impaired (MCI n = 16, Alzheimer's disease dementia n = 26), data obtained November 2017 to January 2019]. Associations between plasma NfL and imaging-derived measures were examined voxel-wise using linear regression (cross-sectional) and linear mixed effect models (longitudinal). Cross-sectional analyses in both cohorts showed that plasma NfL was associated with PET findings in brain regions typically affected by Alzheimer's disease; associations were specific to amyloid PET in cognitively unimpaired and tau PET in cognitively impaired (P < 0.05). Longitudinal analyses showed that NfL levels were associated with grey/white matter volume loss; grey matter atrophy in cognitively unimpaired was specific to APOE ε4 carriers (P < 0.05). These findings suggest that plasma NfL increases in response to amyloid-related neuronal injury in preclinical stages of Alzheimer's disease, but is related to tau-mediated neurodegeneration in symptomatic patients. As such, plasma NfL may a useful measure to monitor effects in disease-modifying drug trials. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
6. 18F-MK-6240 PET for early and late detection of neurofibrillary tangles.
- Author
-
Pascoal, Tharick A, Therriault, Joseph, Benedet, Andrea L, Savard, Melissa, Lussier, Firoza Z, Chamoun, Mira, Tissot, Cécile, Qureshi, Muhammad Naveed Iqbal, Kang, Min Su, Mathotaarachchi, Sulantha, Stevenson, Jenna, Hopewell, Robert, Massarweh, Gassan, Soucy, Jean-Paul, Gauthier, Serge, and Rosa-Neto, Pedro
- Subjects
NEUROFIBRILLARY tangles ,FRONTOTEMPORAL lobar degeneration ,MILD cognitive impairment ,COGNITION disorders ,CEREBRAL amyloid angiopathy ,ALZHEIMER'S disease ,ALZHEIMER'S patients ,RESEARCH ,NEURONS ,CROSS-sectional method ,RESEARCH methodology ,ISOQUINOLINE ,RADIOISOTOPES ,EVALUATION research ,MEDICAL cooperation ,FLUORINE isotopes ,COMPARATIVE studies ,RESEARCH funding ,EARLY diagnosis - Abstract
Braak stages of tau neurofibrillary tangle accumulation have been incorporated in the criteria for the neuropathological diagnosis of Alzheimer's disease. It is expected that Braak staging using brain imaging can stratify living individuals according to their individual patterns of tau deposition, which may prove crucial for clinical trials and practice. However, previous studies using the first-generation tau PET agents have shown a low sensitivity to detect tau pathology in areas corresponding to early Braak histopathological stages (∼20% of cognitively unimpaired elderly with tau deposition in regions corresponding to Braak I-II), in contrast to ∼80-90% reported in post-mortem cohorts. Here, we tested whether the novel high affinity tau tangles tracer 18F-MK-6240 can better identify individuals in the early stages of tau accumulation. To this end, we studied 301 individuals (30 cognitively unimpaired young, 138 cognitively unimpaired elderly, 67 with mild cognitive impairment, 54 with Alzheimer's disease dementia, and 12 with frontotemporal dementia) with amyloid-β 18F-NAV4694, tau 18F-MK-6240, MRI, and clinical assessments. 18F-MK-6240 standardized uptake value ratio images were acquired at 90-110 min after the tracer injection. 18F-MK-6240 discriminated Alzheimer's disease dementia from mild cognitive impairment and frontotemporal dementia with high accuracy (∼85-100%). 18F-MK-6240 recapitulated topographical patterns consistent with the six hierarchical stages proposed by Braak in 98% of our population. Cognition and amyloid-β status explained most of the Braak stages variance (P < 0.0001, R2 = 0.75). No single region of interest standardized uptake value ratio accurately segregated individuals into the six topographic Braak stages. Sixty-eight per cent of the cognitively unimpaired elderly amyloid-β-positive and 37% of the cognitively unimpaired elderly amyloid-β-negative subjects displayed tau deposition, at least in the transentorhinal cortex (Braak I). Tau deposition solely in the transentorhinal cortex was associated with an elevated prevalence of amyloid-β, neurodegeneration, and cognitive impairment (P < 0.0001). 18F-MK-6240 deposition in regions corresponding to Braak IV-VI was associated with the highest prevalence of neurodegeneration, whereas in Braak V-VI regions with the highest prevalence of cognitive impairment. Our results suggest that the hierarchical six-stage Braak model using 18F-MK-6240 imaging provides an index of early and late tau accumulation as well as disease stage in preclinical and symptomatic individuals. Tau PET Braak staging using high affinity tracers has the potential to be incorporated in the diagnosis of living patients with Alzheimer's disease in the near future. [ABSTRACT FROM AUTHOR]
- Published
- 2020
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.